id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1996-D-0048-0006,FDA,FDA-1996-D-0048,Guidance for Industry Q3B(R2) Impurities in New Drug Products,Other,Guidance,2021-10-27T04:00:00Z,2021,10,2021-10-27T04:00:00Z,,2021-10-27T16:06:56Z,,0,0,0900006484dfa462